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ABSTRACT 
The aim of this research was to test the effect of follistatin (Fst) and or Peroxisome 
Proliferator co-activator 1 alpha (PGC-1) overexpression with recombinant adeno 
associated viral vectors (rAAV) in modulating muscle function. The introduction 
(chapter I) was written to provide background information on skeletal muscle 
physiology. Chapter I focused on skeletal muscle function, the regulation of its mass 
and metabolism. Chapter II described material and methods and it was followed by 
experimental chapters.  
The first aim of this thesis was to test the anti-atrophy effect of rAAV-Fst. The results 
in chapter III showed that rAAV-Fst increases muscle mass and protein synthesis. 
This response was capable of preventing non-degenerative muscle wasting (nerve 
and tendon injury) in C57/BL6 mice when delivered 2 weeks prior to injury. However, 
muscles treated with rAAV-Fst failed to respond when the vector was delivered at 
the time of injury. The results suggested an intact nerve and mechanical load are 
required for Fst-mediated muscle growth. 
The second aim of this thesis was to test the metabolic effect of Fst. In chapter IV, 
the results showed that 2 week treatment with rAAV-Fst led to decreased glucose 
uptake and fatty acid metabolism. In parallel, rAAV-Fst produced an increase in the 
proportion of diacylglicerol (DAG) esterification and accumulation. Despite this, 
rAAV-Fst treated muscles had increased sensitivity to insulin-meditated glucose 
uptake and decreased response to contraction-induced glucose uptake. These 
suggested a positive role for rAAV-Fst induced growth in the regulation of glucose 
metabolism. 
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The third aim of this thesis was to test the effects of rAAV- PGC-1, rAAV-Fst and 
their combination. The results in chapter V showed that acute (2 weeks) post-natal 
delivery of rAAV-PGC-1 offered no protection against denervation. Chronic 
treatment (8week) with rAAV-PGC-1 improved glucose metabolism, reduced peak 
force and increased resistance to fatigue. On the other hand, chronic treatment with 
rAAV-Fst produced larger and stronger muscles. Co-delivery of rAAV-PGC-1 and 
rAAV-Fst resulted in very large muscles, however they produced less force and had 
decreased resistance to fatigue. These results suggested that PGC-1 and Fst exert 
some adaptations that are mutually exclusive. 
A general discussion and conclusion (chapter VI) was written to highlight the most 
important findings of this thesis and debate about the importance and implications of 
this research.  
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General introduction 
The health of skeletal muscle plays a key role in our lives 
Skeletal muscle, without doubt the largest organ of the human body, plays a 
fundamental role in human health and wellbeing. Skeletal muscle constantly 
adapts its mass and metabolism to accommodate demands in response to 
health status. In adults, interventions promoting muscle mass increase 
(hypertrophy) have positive health consequences such as delaying the onset 
and reducing severity of disease (1). In contrast, skeletal muscle loss 
(atrophy) aggravates the seriousness of health affecting disorders (2-4). In 
addition, atrophy decreases the quality of life in the elderly and reduces their 
ability to respond and/or recover from disease (5). The loss of muscle mass 
has been associated with unfavourable changes in the metabolism of 
proteins, carbohydrates and lipids (6, 7). Atrophy is also believed to contribute 
to the burden of metabolic disorders (8-11). These are the reason why the 
direct and indirect economic costs associated to atrophy are believed to add 
as much as half of the Australian yearly health expenditure (12). 
Unfortunately, there is no treatment against atrophy. Hence, new therapeutic 
approaches to tackle muscle atrophy could help improving many lives and 
save billions of dollars.  
Developing new approaches to improve skeletal muscle health is 
imperative  
It has been long known that the ability to ambulate and exercise is 
fundamental to human life health. The evidence pointing to exercise as a 
potential therapeutic intervention to prevent or ameliorate cardiovascular 
CHAPTER I – INTRODUCTION 
26 
 
conditions (obesity, heart disease), cancer,  osteoporosis and atrophy (13) 
keeps growing. However, one of the major drawbacks of modern society is 
the lack of exercise. Sedentary behaviours are on the rise and contributing to 
the alarming increase in (mostly preventable) metabolic disorders such as 
insulin resistance, obesity and diabetes. Adding to this problem is that as a 
result of today’s improved health care, there is an increase in the elderly 
population as well as the number of patients critically and chronically ill 
confined to hospital beds (14). Unfortunately, the elderly, ill and sedentary 
people cannot benefit from regular exercise. Hence, there is a need to better 
understand the biology of muscle and create interventions to improve it. 
Fortunately, there is hope of new avenues of therapeutic developments such 
as novel ways to deliver transgenes that allow us to manipulate the 
physiology of skeletal muscle in ways never seen before (15-18). 
Using gene therapy to enhance skeletal muscle function 
Identification of novel methods to mimic or potentiate the effects of exercise is 
a long standing, albeit elusive medical goal. Lately, new tools for controlling 
genes in non-transgenic animals exist via administrating recombinant adeno-
associated viral vectors (rAAV). These vectors provide the means to explore 
the physiological significance of controlling gene expression in post-natal 
muscle. In the context of exercise-related adaptation of muscle, rAAV rise 
high above the rest by their ability to allow tissue specific, long lasting and 
non-pathogenic transgene expression. Two target proteins that could benefit 
from their delivery with viral vectors are Follistatin (Fst) and Peroxisome 
Proliferator-activated receptor gamma co-activator 1 alpha (PGC-1). A body 
of evidence points to Fst as a potential positive regulator of muscle mass in 
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health and disease (19-21). PGC-1, on the other hand, is a key protein 
involved in modulating skeletal muscle’s oxidative metabolism (22-24).  
The following introductory chapter presents a review on the relevant literature 
about the origin of skeletal muscle and the key regulatory pathways involved 
in skeletal muscle growth and metabolism. In particular, the introduction 
highlights how Fst and or PGC-1 in the context of atrophy and metabolism.  
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Introduction 
Fundamental muscle biology 
Musculature formation (myogenesis) is a sophisticated process beginning as 
early as the embryo has three defined layers: the outer, inner and middle 
layer (or ecto-, endo- and mesoderm) [reviewed in (25-28)]. Myogenesis 
occurs within the mesoderm’s compartment called myotome (for muscle) (29). 
In the myotome, myogenic progenitor cells (myoblasts) align and fuse into 
multinuclear mature muscle cells (myotubes) as a part of their commitment to 
form myofibres, the building blocks of muscle (30). Once adult skeletal muscle 
is formed, it still retains a subpopulation of dormant myoblasts (satellite cells) 
which become active to support muscle repair, growth and maintenance (27, 
28, 31-33).  
A key structural characteristic of skeletal muscle is that myofibres are made of 
longitudinally arranged sacomeres containing mechanical filaments which 
appear like “light” and “dark” bands when their protein/filament arrangement is 
observed under high magnification (Figure 1A). Light bands or I-bands 
comprise parallel arrays of thin filaments containing Actin (34) (Figure 1B). 
Actin, the most abundant protein in skeletal muscle (35), spans its filaments 
into the dark bands or A-bands where the myosin-containing thick filaments 
are found. Actin and myosin interact  to create tension (also known as muscle 
contraction) via a process known as cross-bridge action (36) (Figure 1C). 
Generation of tension and cross-bridge action are discussed in section 
‘Mechanics of muscle contraction’ (page 32). Muscle contraction is controlled 
by influx of Ca2+ and depends on tropomyosin and troponin to generate force 
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(37). Many accessory proteins, including an additional filament system made 
of Titin or nebulin, span through the sarcomere. For example, the boundary of 
the sarcomere (Z-discs) contain a capping protein, CapZ, and serves to 
anchor the actin, titin and nebulin filaments (38) and is implicated in 
mechanosensation and signalling (39). Also found in the muscle cells are 
invaginations of its membrane (also called sarcolemma) corresponding to 
perpendicularly penetrating transverse tubules (T-tubule) (Figure 2). T-tubules 
unify the depolarisation of the muscle membrane allowing a synchronised 
contraction. 
The periphery of muscle cells is characterized by the presence of multiple- 
nuclei (Figure 2). These nuclei result from recruitment and fusion of single-
nuclei muscle cells (myoblasts) early in development. Also in the periphery it 
is possible to observe that the sarcolemma is in contact with controlling motor-
nerve (Figure 2). Each of these sites is known as a neuromuscular junction 
(NMJ). Motor-nerves originate at motorneurons, a part of the specialised 
brain-to-muscle circuit (cell body, neural processes and NMJ) directing the 
electrical control of skeletal muscle. One motor unit can innervate up to 1900 
muscle fibres (such as the gastrocnemius). During development, motor units 
reach immature muscle fibres with multiple axons. Once these myogenic 
fibres are contacted they start to differentiate into primary and secondary 
myotubes [reviewed in (40)]. Pre-natal muscle fibres undergo myogenesis 
simultaneously with the establishment of multiple motorneurons. After birth, 
the immature muscle undergoes a process of motorneuron elimination (41), 
which correlates with a progressive change from embryonic to mature myosin 
heavy chain (MyHC) composition (42). Motorneuron elimination leads to a 
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single axon attached per fibre in the adult muscle (43). Big axons derived from 
big motorneurons recruit the less active (fast) fibres, while the opposite is the 
case of very active (slow) fibres (44).  
 
 
Figure 1. A myofiber containing dark and light striations and external nuclei (A). Each 
myofiber is composed of aligned myofibrils on which the light bands are rich in actin 
and the dark bands correspond to enrichment of myosin overlapping with Actin (B). 
Actin and myosin are organised in a structure called sarcomere (C) which is the basic 
contractile unit of the muscle (45). 
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Figure 2 shows a myofiber contacted by a motorneuron via axons that contact the 
sarcolemmal NMJ. A myofiber contacts a single axon at multiple sites allowing a 
coordinated contraction among all the myofibrils at the same time (45). 
 
There are many specialized structures in the muscle cells. Microtubules are 
the building blocks of an integration network. Microtubules link the 
sarcolemma, Golgi complex and nuclei {Kano, 1991 #1442}. Costameres are 
another structure found affixed to the sarcolemma. Costameres contribute to 
mechanosignal transduction and provide an anchoring site for the 
extracellular matrix (ECM) proteins. The ECM is vital in preserving the 
structural integrity of the sarcolemma during muscle contraction.  
There are other important networks that support the correct function of 
skeletal muscle. The first, focal-adhesions, anchor the ECM to actin proteins 
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via integrins. Integrins are involved in myofibril assembly and 
mechanosensing [reviewed (46)]. The second is known as the dystroglycan 
complex (DCG). The DCG hosts dystrophin in its core and binds the 
cytoskeleton to the ECM [for details see (47-49)]. Genetic disorders affecting 
the DCG are responsible for the most common class of genetic myopathy, 
Duchenne Muscular Dystrophy (DMD). The third is the spectrin/ankyrin 
complex which is situated in the Z-line and M-lines (50-54).  
Skeletal muscle force is generated from the interaction between myosin and 
actin, two structural proteins with a contractile function. There are two types of 
Myosin, myosin heavy chain (MyHC) and myosin light chain (MyLC). MyHC 
has two clear portions, the head and the rod (55). The head interacts with 
actin via an active process requiring adenosine triphosphate (ATP) (56). 
There are different myosin isoforms that fall under two main categories, fast or 
slow, depending on the speed  they act (57, 58). MyHC type IIa (MyHCIIa), 
type IIx (MyHCIIx) (human) and type IIa (MyHCIIa) (mouse) are predominantly 
fast isoforms expressed in skeletal muscle while MyHC type I (MyHCI) is 
predominant slow (59). Other classes of myosin are also found in the heart, 
extra ocular muscles and during development, however their discussion goes 
beyond the scope of this review [reviewed in (60)]. Muscle contractions not 
only generate the force required for movement, but also they are capable of 
modify the properties of skeletal muscle (61-64). The following section 
describes the mechanics of muscle force as a preamble to the insights of 
muscle health and its post-natal regulation.  
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Mechanics of muscle contraction 
A voluntary muscle contraction is the end result of a chain of events. Electric 
waves generated from the brain travel through the central nervous system 
(CNS), the motor neurons and axons. Once an electric pulse reaches the 
sarcolemma, it leads to influx of ions through calcium-dependent channels 
(65). Influx of calcium ions (Ca2+) causes the release of acetylcholine into the 
extracellular space (between the motor neuron terminal and the motor end 
plate). Ca2+ binds to nicotinic acetylcholine receptors and opens the 
sodium/potassium channels. This process causes the membrane to become 
depolarised, triggering an action potential. Spreading of the action potential 
occurs through the network of T-tubules, depolarising the inner portion of the 
muscle fibre. Depolarisation activates voltage-dependent calcium channels 
(dihydropyridine receptors) which are in close proximity to calcium-release 
channels (ryanodine receptors) in the adjacent sarcoplasmic reticulum. 
Activated voltage-gated calcium channels physically interact with calcium-
release channels causing the sarcoplasmic reticulum to release calcium. The 
increased cytosolic concentration of calcium leads to its binding to troponin C 
which modulates tropomyosin (66). This causes an allosteric change in 
troponin protein T which in turns allows tropomyosin to move, unblocking the 
myosin binding sites (67). Myosin binds to the newly uncovered binding sites 
on the actin filament to facilitate the power stroke (68). As a result, ADP and 
inorganic phosphate are released. This will pull the Z-bands towards each 
other, thus shortening the sarcomere (muscle tension). In order to relax, ATP 
binds to myosin, allowing it to release actin. Myosin then hydrolyses the ATP 
and uses it to return to an initial pre-contraction state and active re-synthesis 
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of ATP takes place. While the above steps are occurring, special transporters 
actively pump calcium back into the sarcoplasmic reticulum to maintain its 
ionic concentration in the sarcoplasm. Thus, the tropomyosin-troponin 
complex again covers the binding sites and the sarcomere returns to initial 
state. The maximal tension produced during muscle contraction correlates 
with the number and size of fibres recruited, thus it is generally believed that 
muscle mass is proportional to force generating capacity. Therefore, it is easy 
to understand why maintenance of muscle and function is important for overall 
wellbeing. 
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Skeletal muscle health 
Skeletal muscle, nearly half of a human's body mass, is a unique tissue that 
significantly contributes to an individual's locomotion, metabolism and overall 
quality of life. The main determinants of skeletal muscle health are its mass 
and metabolism (handling of carbohydrates, lipids and proteins).   
Changes in skeletal muscle mass and metabolism are closely interconnected. 
In healthy individuals, developmental growth and exercise are the main 
factors affecting energy requirements (69). During childhood and particularly 
in teenagers, circulating growth factors produce an incremental gain in muscle 
mass and energy requirements/utilization. However, once developmental 
maturity peaks and circulating growth factors decline, maintenance of muscle 
function relies on regular exercise and diet. Although the concept is very 
simple: exercise and stay healthy, a vast percentage of the world’s population 
suffers from the deleterious effects of a sedentary lifestyle. Often, elderly and 
chronically ill people also suffer the consequences from lack of exercise. In 
combination, these populations represent a burden for the public and private 
medical systems. Thus, there is a clear need for treatments with the potential 
to enhance muscle function in people that are not doing or can’t do enough 
physical activity.  
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Regulation of post-natal skeletal muscle growth 
Muscle mass gains occur during developmental growth, in response to growth 
factors (70, 71), dietary changes and increased exercise load (72). Upon 
repeated load, skeletal muscle increases its size, mass and strength. 
Increasing skeletal mass involves some or all the following processes: 
addition of myogenic precursor cells (satellite cells and other precursor cells) 
(73-77), increased number of fibres (hyperplasia) (78, 79) and/or muscle fibre 
hypertrophy (80) . 
The inclusion of satellite cells to the existing myotubes occurs mainly during 
developmental growth and post-natal muscle repair. Upon activation, satellite 
cells proliferate, differentiate and fuse with existing myotubes (77). 
Histologically, newly fused satellite cells appear at the centre of cross 
sectional muscle fibres. As myotubes mature, satellite cells migrate to the 
periphery of the muscle cell [reviewed in (81)] (Figure 3).  
 
Figure 3 shows an schematic representation of the steps required for satellite cells to 
become part of myofibres [Figure published by (81)]. 
 
Hyperplasia is a process that rarely occurs in adult muscle, but it is rather 
confined to pre-natal development. However, there are reports of post-natal 
hyperplasia. It would appears that this takes place when an existing myofiber 
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invagination branches and splits (82) or during acute phases of growth in 
rodents (83).  
The most prominent form of post-natal muscle growth is skeletal muscle 
hypertrophy. Muscle hypertrophy is controlled by two contrasting processes, 
protein synthesis (anabolism) and degradation (catabolism) (84) [reviewed in 
(85-91)]. These processes react in response to natural and synthetic 
interventions. The lessons learnt from physiological growth has led to the 
development of many synthetic approaches for the regulation of muscle mass 
(92, 93). These interventions have been designed to mimic, amplify or block 
subset signalling pathways implicated in muscle growth/wasting (87, 94, 95) 
and may in turn impact in hundreds, if not thousands, of muscle remodelling 
genes/gene regulators (96-103). This thesis focused in the Thymona viral 
oncogene (Akt)/ mammalian target of rapamycin (mTOR) (104) and the 
Transforming Growth Factor Beta (TGF-) pathways (105, 106) for their 
protagonist role in the regulation of mass. In addition, this thesis discussed 
the role of Peroxisome Proliferator co-activator 1 alpha (PGC-1) as a key 
regulator of muscle metabolism. 
The Akt/mTOR pathway 
Activation of Akt/mTOR is one of the key events involved in exercise mediated 
muscle growth (107-110). An increase in Akt phosphorylation [serine residue 
473 (Ser473) threonine 309 (Thr309)] can command the up-regulation of 
protein synthesis and down-regulation of protein degradation. The latter 
occurs via phosphorylation (and inhibition) of Fork Head Transcription Factor 
1 (FKHR) also known as forkhead box O (FoxO) (111-116). Akt controls 
protein synthesis, primarily, via mTOR (104, 117) through inhibition of 
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glycogen synthase kinase 3 beta (GSK-3) (112). Phosphorylation of GSK-3 
removes its inhibition of elongation initiation factors (eIFs) that influence 
translation initiation resulting in increased protein synthesis in skeletal muscle 
(118). mTOR also acts through phosphorylation of protein 70 S6 kinase 
(p70S6K) which in turn phosphorylates and represses the catabolic activity of 
the eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) also 
known as PHAS-1 (87, 88) (Figure 4). Additionally, phosphorylated 4E-BP1 
can exert a positive modulation loop by binding to rapamycin TOR kinase 
associated protein (raptor) and further activating mTOR (119). 
Phosphorylation of both p70S6K and 4E-BP1 are common readouts of 
anabolic processes (112). Interestingly, there is evidence of a molecular 
‘bridge’ (Ying-Yang 1, YY1) between mTOR and PGC-1 (120) (Figure 4). 
The existence of a target such as YY1 suggests that therapeutic interventions 
designed to induce muscle growth could also influence fibre type composition 
and metabolism, or vice versa. However, not much attention has been paid to 
investigating the potential additive effects of combining interventions to 
increase muscle mass and improve metabolism. 
Akt has been the focus of intense effort in developing an intervention to 
enhance muscle function. For example, chemical activation of Akt protects 
against sepsis in mice (121). Also, exogenous delivery of recombinant human 
IGF-1 (an upstream activator of Akt) improves muscle function in dystrophic 
rodents (122) and enhances the benefits of gene therapy (123). IGF-1 
treatment seems safe (without side effects humans) (124) and has the 
potential to improve body composition and metabolism in dystrophic patients 
(125, 126). Unfortunately, there are reasons to believe that stimulation of Akt 
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via IGF-1 will not produce substantial functional improvements (71). However, 
there is evidence to support that activation of Akt via TGF- signalling 
inhibition could have better results (127). 
 
 
 
 
Figure 4, as shown by Sandri. M et al. 2006 (128), shows how repeated muscle 
contraction drives the production of IGF-1, stimulating protein synthesis and fibre 
hypertrophy as well to down-regulating protein degradation via the Akt axis. In 
addition, repeated bouts of contraction allow positive changes in intracellular levels of 
calcium driving a muscle slow-fibre phenotype gene program which includes the up-
regulation of PGC-1. PGC-1 further down-regulates protein degradation by halting 
the activity of FoxO. 
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The TGF- signalling pathway 
It has been over 20 years since muscle growth inhibiting proteins extracted 
from injured muscles were baptised as  TGF- (129). Since then, Dr. Lee and 
colleagues found that the absence of a particular type of TGF- family ligand, 
myostatin or growth differentiation factor (GDF)-8, is responsible for the 
muscularity in Belgium Blue cattle (130). It has also been revealed that lack of 
myostatin increases muscle mass across different species (Figure 5). 
Therefore, is easy to understand why inhibiting TGF- signalling and 
myostatin are attractive in the quest of targets against muscle wasting (131). 
When present, myostatin participates in cellular differentiation (132, 133) and 
inhibits growth during  wasting conditions (134). Absence, (135), direct or 
indirect inhibition of myostatin induces muscle growth and improves (in 
rodents) diseases such as Duchenne Muscular Dystrophy (19, 136, 137), 
Amyotrophic Lateral Sclerosis (ALS) (138) and cachexia (139, 140). It is also 
believed that myostatin inhibition increases the success of myoblast 
transplantation (19, 141).  
 
Figure 5 shows the effect of TGF- inhibition by myostatin deletion in mice 
(142), cattle, dog and human (7 months old) (143). 
 
Myostatin, as well as many other TGF- family ligands, signals through a 
series of receptors and effector proteins to repress growth (142), possibly via 
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down-regulation of mitotic events and up-regulation of apoptosis. Activation of 
this pathway relies on the availability of ligands such as myostatin, TGF-, 
bone morphogenic protein (BMP) or Activin. These proteins are secreted as a 
pro-peptide that is later cleaved to yield the active protein (144, 145). TGF- 
family ligands bind to type II and type I trans-membrane serine/threonine 
kinase receptors in the membrane of the muscle cell (146). Myostatin was 
originally identified to bind both the Activin type II receptor B, which can be 
inhibited by Fst. Once the heteromeric ligand-receptor complex forms, the 
signal propagates towards the nucleus via phosphorylation of down-stream 
effector protein small mother of decapentaplegic (Smad) protein  (147). 
Activated Smad proteins (1-3,5, & 8) complex with co-operative Smad isoform 
4 (Smad4) to regulate hundreds of gene targets, many of which are involved 
in muscle growth (148) (Figure 6).  
 
 
Figure 6 shows ligand binding to TGF receptors I and II to induce their activation 
assembling of a receptor complex that phosphorylates and activate SMAD. 
Phosphorylated SMAD is then joined by collaborative Smads (co-Smads) to 
synergistically bind to DNA and modulate transcriptional responses in the presence 
of cofactors, co-activators and co-repressors (149). 
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There are many ways to manipulate the TGF- pathway. For example ligand 
activity/availability can be modulated via blocking the ligand with pro-peptides 
(150) or with the antagonists such as growth factor-associated serum protein-
1 (Gasp-1) (151). Introduction of dominant negative receptor competitors 
(149) and degradation of Smad proteins by the E3 ubiquitin ligases Smurf 1 
and- 2 (152) can also deter the activity of TGF-. Inhibition of Smad2 and 3 
causes myotube hypertrophy via down-regulation of protein degradation and 
through mTOR dependent increments in protein synthesis (153). Increasing 
the levels of the TGF- antagonist Smad7 also promotes skeletal muscle 
differentiation and removes the myostatin repression over muscle growth in 
vitro (154). 
Therapeutic efforts to improve muscle function via inhibition of TGF- have 
shown promising results. Delivery of a compound acting as an angiotensin II 
receptor antagonist commonly used to treat high blood pressure, Losartan, 
has shown to inhibit myostatin rendering improvements in muscle remodelling 
and protection against disuse atrophy in sarcopenic mice (155). Delivery of 
antibodies against myostatin showed amelioration of the pathophysiology of 
dystrophies (156, 157). A similar approach is currently being tested in cancer 
patients in a Phase II trial by Eli Lilly (cinicaltrials.gov identifier 
NCT01505530). Delivery of pro-peptides that can bind-to and block Myostatin 
in solution (150, 158) or by plasmid (159) have also shown to elicit muscle 
growth and improve muscle function. Interestingly, it has been found that 
inhibition of myostatin via pro-peptides may be better at improving muscle 
function than anti-Myostatin antibodies (136). Encouraging results have also 
been produced from delivering short interfering hairpin against myostatin. This 
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method has shown to increase muscle mass in rodents (160). Other 
alternatives to manipulate this pathway are the inhibition of Activin receptor 
type II B (ActRIIB) via rAAV delivery of a soluble receptor inhibitor (161), a 
dominant negative receptor (141) or antibody-targeted receptor inhibitors 
(162, 163). They all have shown encouraging results as a therapeutic 
candidate against muscle wasting. In addition, Acceleron Pharma/Shire 
developed ACE-031, a ActRIIB receptor chimera with strong capacity to 
decrease body fat, increase muscle mass and improve insulin sensitivity (138, 
164, 165). However, ACE-031 has been discontinued given that a phase II 
clinical trial raised safety concerns (clinicaltrials.gov identifier NCT01099761).  
While the safety concerns about ACE-031 have not been reported, it is 
possible that this molecule had off-target effects given its lack of substrate 
specificity. As shown below (Figure 7), immunoprecipitation of the ActRIIB 
binds many TGF- ligands.  
 
Figure 7 (Souza T A et al. 2008) shows specific and direct binding between ActRII- 
receptors and the ligands myostatin, Activin A, B, and AB, and BMP-9, -10, and -11 
(166). 
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In addition to the aforementioned strategies, it is also possible to suppress 
TGF- signalling via the overexpression of inhibitory binding proteins (167), 
such as BMP Activin membrane-bound inhibitor (Bambi) (168, 169) and 
Follistatin (170). For the future TGF--based therapeutics, it is important to 
take into account that it is important to maintain a degree of activation of this 
pathway for the adequate control of cancer, reproduction and coagulation 
(171-173).  
Follistatin 
Inhibition of TGF- ligand family members, for example by Fst, is a potential 
strategy against muscle wasting. Clinical studies have shown that 
endogenous Fst levels are compromised in models of muscle wasting such as 
chronic heart failure (rats) (21) or chronic obstructive pulmonary Disease 
(COPD, humans) (174) while the opposite effect is observed during treatment 
with deacytelase inhibitors (175) – a model of muscle hypertrophy. In line, 
transgenic overexpression of Fst causes pronounce muscle hypertrophy in 
skeletal muscle of healthy rodents (19, 176, 177) and primates (17).  
Pre-clinical studies in rodents have shown that Fst-based therapies are a 
promising path against muscle atrophy. Delivery of recombinant Fst lessens 
the severity of a mouse model of Spinal Muscular Atrophy (SMA) (177) and 
transgenic expression of Fst (20, 178), Fst-related proteins (179) or Fst-based 
myostatin inhibition (177) increased muscle mass and improved SMA and 
DMD (rodents). On the down side, concerns have been raised about the 
safety of Fst therapies as it may affect the reproductive system via 
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suppression of the follicle-stimulating and the hypothalamic–pituitary–gonadal 
axis (180). Hence, the future of Fst relies in finding ways to deliver and 
constrain its effects within muscle.  
First was first isolated as an inhibitor of follicle-stimulating hormone (181). 
There are two alternative splices of Fst, a long-circulating version (Fst315) 
and a shorter non-circulating version (Fst288) (176)- ; the later having a 
higher inhibitory capacity than its longer version (170). Structural studies have 
revealed that Fst binds to TGF- family ligands (182) and facilitates their 
cellular uptake and degradation (183). In skeletal muscle, endogenous 
expression of complete or partial forms of Fst blocks myostatin (179) (Figure 
8) and Activin (184). As mentioned earlier, this removes the inhibitory growth 
effect of the TGF- signalling pathway. In turn, this seems to promote growth 
through an increase in protein synthesis (185) independent of satellite cell 
activation (78).  
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Figure 8 adapted from Aversa, Z. et al 2011 shows the activation of TFG- by 
Myostatin and the antagonists Follistatin and Follistatin Related Gene (FLRG) (186). 
 
Potentially, Fst drives an increase in protein synthesis after activating the non-
canonical Akt/mTOR pathway (127) and its downstream target P70S6K (185). 
There is evidence to support a protagonist role for the Akt pathway in Fst-
induced growth mice (127, 187). However, it is so far unknown whether 
manipulation of this pathway with Fst treatment can protect against muscle 
mass loss as a result of denervation or tenotomy.  
It is also possible that Fst increases muscle mass via inhibition of protein 
degradation. It is known that the TGF- signalling pathway control the 
expression of “atrogenes” (a term referring to genes involved in atrophy, 
reviewed in later section about the Ubiquitin proteasome pathway) via cross 
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talk with the Akt pathway (188). However, no studies have looked at the effect 
of Fst on protein breakdown. Interestingly, there is growing evidence 
suggesting that regulation of atrogenes is also under the control of PGC-1 
(189-191). 
 
PGC-1  
In humans, endurance exercise progressively improves performance in long 
duration sporting events by producing positive changes within skeletal 
muscles (97) as well as physiological adaptations in the cardio-pulmonary, 
endocrine and neuromuscular systems (192). Endurance training regulates 
the expression of slow-twitch contractile fibres, mitochondria and fatty acid 
usage (193-196) and also improves body composition and ameliorates the 
severity of metabolic disorders (197). Endurance exercise activates a number 
of transcriptional regulators as well as protein kinases that contribute to 
metabolic remodelling (89). One of these key protein is PGC-1 (23, 198-200) 
(Figure 9).  
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Figure 9 (left) shows a PGC-1 as the mediator between extracellular stimuli and 
gene regulation. On the right, wild type (WT) and transgenic (TG) mice 
overexpressing PGC-1 have darker red muscle colour suggesting a shift towards an 
oxidative phenotype (199). 
 
PGC-1 is a transcriptional co-activator with tissue-specific activity (201) that 
was first discovered by Spiegelman and co-workers (22). PGC-1 is 
expressed predominantly in metabolically active tissues such as brown fat 
(22, 23), liver (76, 202, 203), cardiac muscle (204-206) [reviewed in (207)], 
nervous system (208, 209), cancers (210, 211) and endocrine organs (212) 
but also in many other not so metabolically active (213-216).  
In muscle, PGC-1 has been described as a  master ‘switch’ in the control of 
mitochondrial biogenesis (201, 217-219), adult skeletal muscle phenotype 
(63, 96, 201, 220-223), glucose transport (224), lipid utilization (225), the 
muscle’s circadian clock (226) and skeletal muscle protein turnover (189, 227-
230) [reviewed in (201, 206, 217, 231, 232)]. Increased levels of PGC-1 are 
found following increased motor nerve activity, increased energy demand 
(220) and cross-innervation (with slow-twitch nerves) (199). Increased levels 
of PGC-1 have been associated to the beneficial effects of low (198, 233) 
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and high intensity (234) exercise  and electric stimulation (235). There is 
evidence to support a role for increased PGC-1 levels during muscle 
hypertrophy, such is the case after treatment with beta adrenergic synergists 
(236) and high protein diets (237). However, an increase PGC-1 has also 
been measured  during detrimental situations such as energy deprivation 
(238), cachectic cytokine exposure (239), glucocorticoids and microtubule 
inhibitors (230) and protein synthesis inhibitor treatments (230). 
On the other hand, decreased PGC-1 levels are often found as a 
consequence or in the aetiology of myopathies (99, 240, 241), high fat diet 
(242), sarcopenia and age related metabolic disease (243). Down regulation 
of PGC-1 is also a reflection of detrimental health conditions such as 
diabetes type II [reviewed in (232)], insulin resistance (244), disuse and 
denervation-induced muscle wasting (99), obesity (225), myopathies (245), 
chronic obstructive pulmonary disease (COPD) (240), amyotrophic lateral 
sclerosis (ALS) (246) and Duchene Muscular Dystrophy (229) suggesting that 
its adequate regulation may play a key role  at the onset or during the 
progression of conditions accelerating muscle breakdown.  
PGC-1 protein binds directly to transcription factors through lysine rich 
protein interactions involving the LXXLL motif. This couples PGC-1 with most 
nuclear receptors through its N-terminal (247), this relies on its nuclear over 
cytosolic localization (248). In skeletal muscle, PGC-1 interacts with 
estrogen related receptor alpha (ERR) (249), peroxisome proliferator 
activated receptor (PPAR) gamma (250), PPAR delta (251), Glucocorticoid 
Receptor (GR) (230), Nuclear respiratory factor 1 (NRF1) (252) and Ying 
Yang 1 (YY1) (120), however in other tissues PGC-1 has shown the ability to 
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co-activate other targets such as retinoid x receptor alpha (RXR) (253) 
(HeLa cancer cells) or hepatocyte nuclear factor four alpha (HNF4) (203) (rat 
hepatocytes and mouse liver). From the aforementioned targets, it is worth 
mentioning that endogenous up-regulation of PPAR delta mediates/mimics 
many of the beneficial effects of PGC-1 in skeletal muscle. In particular, 
PPAR delta agonists such as the ligand L165041 (254), GW0742 (255) or its 
transgenic overexpression (256) have shown to increase resistance to fatigue. 
Interestingly, PPAR delta has also shown to negatively regulate Myostatin 
(254). 
The activity of PGC-1 depends on its transcriptional regulation and post-
translational modifications. Transcriptional regulation involves the activation of 
Myocyte Enhancer Factor-2 (MEF2) a target of calcineurin (257), Akt 
signalling (258) and FKHR or FoxO3a  (236) and cAMP-sensitive elements 
(259). Post-translational modification of PGC-1 in vitro (human and C2C12 
myotubes)  (239, 260, 261) and in vivo (human and mice) (260-262) include 
phosphorylation by the stress-activated cytokine kinase p38 (p38MAPK) 
(239), by adenosine mono-phosphate kinase (AMPK) (263) and Akt (263). 
The ability of PGC-1 to link skeletal muscle growth and cellular respiration is 
via its interaction with YY1 (120). YY1 is a novel transcription factor common 
to mTOR and PGC-1 as seen in mouse muscle and C2C12 myotubes (120). 
As a consequence of exercise, ERR is a key partner of PGC-1 in the 
biogenic program involving the induction of several proteins involved in 
oxidative phosphorylation (249). In addition to driving an oxidative phenotype, 
PGC-1 has shown a protective role against atrophy. 
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In 2006, Sandri et al. found that transgenic overexpression of PGC-1 in mice 
had a protective role against denervation and starvation induced atrophy 
(189). A year later, Hanai et al. showed that PGC-1 overexpression in zebra 
fish and C2C12 inhibited Atrogin-1 and prevented atrophy when exposed to 
statins (lipid lowering drugs known to cause skeletal fibre break down) (228). 
Then, Handschin et al. (2007) reported that transgenic overexpression of 
PGC-1 improves the phenotype of 5 week-old DMD mice (mdx) (229). This 
was followed by Wenz et al. (2009) in a study using muscle-specific 
overexpression of PGC-1 to protect mice against sarcopenia and metabolic 
disease during aging (243). It is also know that myostatin-induced atrophy 
produces an increase in PGC-1 levels after 7 but not 14 days, suggesting a 
natural up-regulation of PGC-1 in response to atrophy (264). Furthermore, 
Fuster et al. (2007) showed that cachectic mice have increased levels of 
PGC-1 and a shift to an oxidative skeletal muscle phenotype (265). Also, 
deletion of PGC-1 has been linked to decreased muscle fibre integrity and 
recovery from exercise (219). Lastly, overexpression of PGC-1 and its 
closely related protein, PGC-1, have shown to attenuate protein degradation 
(266). All together, these data reinforces the idea of PGC-1 acting in an 
internal protective mechanism against atrophy. 
There is also evidence suggesting that PGC-1 is not as important as many 
have believed. For example, it has been found that endurance training can 
lead to similar adaptation in wild type and traditional PGC-1 knockout mice 
(267, 268). Similarly, deletion of PGC-1 in skeletal muscle has no effect on  
exercise capacity and or mitochondrial biogenesis following endurance 
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training (269). In fact, excessive levels of PGC-1 could have detrimental 
health effects such as atrophy, as shown in 2006 by Miura et al. (227).  
Elucidating the potential of PGC-1 in adult muscle has proven elusive (270). 
There is only indirect (pharmacological) evidence of the effects of up-
regulation of PGC-1. The anti-diabetic compounds 5-Aminoimidazole-4-
carboxamide ribotide (AICAR) (271) and the PPAR agonist Rosiglitazone 
(272) have shown to activate PGC-1 to improve energy metabolism. 
However, AICAR did not prevent muscle wasting (266). Given these 
evidence, it is clear that the field is in need of new models that allow testing 
the effects of PGC-1 within the muscle, such as rAAVs.  
Regulation of protein degradation in skeletal muscle 
Muscle loss occurs when the equilibrium between protein synthesis and 
degradation is broken or when the protein synthesis machinery fails to 
replenish degraded proteins. Examples of situations tilting this balance are 
genetic neuromuscular disorders (236), sepsis (273), fasting (274), disuse 
(275-278), paralysis (275, 279) and ageing (280). Excessive break down of 
proteins may also occur as an unwanted consequence of therapeutic 
treatments such as corticosteroids (281-283) and lipid-lowering drugs (284). 
The general consent is that degradation of muscular one or few of the 
proteolytic pathways: the ubiquitin proteasome pathway (UPP) (285), the 
lysosomal pathway (273), calpains (286) and the caspase (or apoptotic) 
protease pathway [reviewed in (287)].  
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The ubiquitin proteasome pathway  
The UPP, sometimes considered as the primary pathway for protein 
degradation in skeletal muscle (114), plays a key role in the turnover of 
skeletal muscle in health and disease. The UPP consists of the Ub-activating 
enzyme (E1), Ub-conjugating or carrier proteins (E2s) and the Ub-protein 
ligase (E3) (288). Targeting of proteins by the UPP begins with the activation 
of Ub at its C-terminus by E1 (289), then Ub is transferred by one of the E2s 
towards the protein of target for degradation. The transference of the Ub is 
catalysed by E3 (a key enzyme conferring specificity and serving as limiting 
step for ubiquination) (289). The Ub tagged protein (ubiquinated) is 
recognised by a multi-catalytic complex (26S proteasome), rendering its 
degradation in the proteasome (290, 291). Once a protein has been 
degraded, its constituents can serve as a substrate for production of energy or 
synthesis of other proteins (Figure 10 right).  
Two muscle specific E3-ligases, muscle specific F-box protein  
(MAFBx/Atrogin-1) and muscle RING-finger protein-1 (MuRF1), have been 
identified as key players in the control of muscle atrophy [reviewed in (292)]. 
These proteins may also play a role in the control of carbohydrate metabolism 
(293-295), suggesting they have multiple roles for the maintenance of muscle 
function. There is still a lot learn from the regulation of Atrogenes. However, it 
is known that nuclear factor kappa beta (NF-) (87, 296, 297) and FoxO (87) 
are two of the main signalling cascades involved in protein degradation. 
NF- is a transcription factor involved in immune, inflammatory and cell 
survival responses (298). Deletion of NF- has shown to increase muscle 
mass, force (in fast oxidative muscle fibres), protect against atrophy and 
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enhance muscle regeneration (299). FoxO (87) is a protein controlling protein 
turnover (113-115). FoxO’s activity has been found under the control of 
calcineurin (300), Creb Binding protein (CBP) family p300 transcription 
complex (301) and Akt (111); most probably via a negative feedback loop 
(302) in models such as muscle repair (303). There is no doubt that future 
therapies against muscle wasting will, in one way or another, target these 
pathways and/or the UPP. 
Degradation of proteins by the lysosome 
The lysosome is an organelle with peptidase activity (304) of vital importance 
for skeletal muscle in vivo and in vitro (114, 174, 305). The lysosome works in 
three ways. Firstly, vesicles can sequester and engulf organelles or proteins 
for their hydrolation in the sarcoplasm. Secondly, the lysosome can directly 
consume its targets. Lastly, similarly to the UPP, a consensus peptide 
sequence binds to a chaperone/co-chaperone complex that allows its 
recognition for lysosomal degradation [reviewed in (306, 307)].  
A key mammalian family of enzyme in the lysosome are the proteases 
cathepsins. Up-regulation of these enzymes are used as markers of protein 
loss (273). Although there is little evidence, it would be interesting to see what 
phenotype results from interventions aimed at inhibiting parts of this pathway 
during muscle atrophy. The following sections offer a summary of each of 
these catabolic pathways. 
The calpain-mediated protein breakdown  
Calcium dependent proteinases, or calpains, are a family of cellular proteases 
that are activated by increases in cytosolic levels of free calcium (308). 
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Calpains play a key role during myogenesis by intervening in cell adhesion, 
migration and fusion (309). Calpains have also shown to mediate atrophy in 
vitro (310) and participate transcriptional regulation in tubular cells (311). 
There are at least 14 calpains. The most important are -calpain,  –calpain, 
calpastatin (inhibitor of the first two) and two muscle specific calpains. 
Calpains (- and -) are heterodimers containing a larger catalytic domain 
and a smaller regulatory fraction (308). The main difference between -
calpain and  -calpain is that the first requires millimolar and the second 
micromolar changes in calcium concentration to modulate their activity (308). 
In general, up-regulation of calpain activity is indicative of accelerated muscle 
wasting (312-314). An exception to the rule is calpain 3a (p94). Down-
regulation of calpain 3a is responsible for some forms of dystrophy (286), a 
trend that is also observed during cancer cachexia and denervation-induced 
wasting (315, 316). For these reasons, calpains are another possible 
therapeutic target against muscle atrophy (Figure 10 left).  
The caspase pathway 
Caspases are highly selective cysteine proteases that cleave proteins at 
aspartic acid residues (317, 318), a fundamental property when it comes to 
breaking down the actomyosin complex (319) (Figure 10 centre). The 
caspase pathway is vital during pre-natal development and also plays a key 
role during diseases leading to atrophy (287). An important caspase, 
caspase-3, is up up-regulated in parallel to the UPP. While the UPP responds 
to transcriptional regulation of atrogenes, caspase activity is increased by 
apoptotic factors released from the mitochondria (320). It is believed that 
activation of caspases occurs via mitochondrial and endoplasmic reticulum 
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signalling pathways (321). Disruption of this pathway has shown to protect 
against atrophy and present another possibility to prevent muscle wasting 
(322, 323).  
 
 
Figure 10 was adapted from Powers S. et al. 2010 (324) and it shows the three main 
paths for protein degradation. On the left is the Calpain pathway, which is sensitive to 
increased cytosolic levels of calcium. The second (centre) is the Caspase mediated 
breakage of muscle proteins. On the right is the Ubiquitin-proteasome system for 
protein degradation. 
 
It is currently unclear whether every proteolytic pathway is involved during the 
breakdown of muscular proteins in different wasting conditions. Thus, it is 
possible that many interventions against muscle wasting will be disease 
specific. For these reasons, muscle wasting conditions have been classified in 
groups and categories according to similarities.  
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Skeletal muscle atrophy, different diseases with a common outcome 
Loss of myotube integrity due to protein defects often results in wasting.  
Often catastrophic (325), defects in proteins such as those in contractile 
apparatus or its interface with the membrane [reviewed in (326)] can be lethal. 
The medical severity of these conditions will often depend on health status, 
gender (327) and the type of muscle affected (189). Although most forms of 
muscle wasting share similar molecular events (328), there are model-specific 
differences that are important to consider when designing new therapeutics 
interventions against muscle wasting (329). 
The Muscular Dystrophy Association (MDA), a leading non for profit health 
agency supporting neuromuscular diseases, has developed a classification for 
muscle-affecting conditions (myopathies). According to the MDA, myopathies 
are classified as dystrophies or disease-states (refer to www.mda.org).  
Muscular dystrophies are mostly considered as inherited wasting conditions 
arising from a defective protein. Below is a list containing the best known 
inherited myopathies. Duchenne Muscular Dystrophy (DMD) is covered in a 
subsequent section.  
 Motor neuron diseases are a group of inherited neurological conditions, 
generally progressive in nature, that affect the nerve cells (330). ALS 
and SMA are the most common forms. 
 Inflammatory myopathies are a group of muscle diseases that involve 
inflammation of the muscles or associated tissues. These diseases 
respond to a genetic predisposition or they can be inherited (331). 
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 Diseases of the neuromuscular junction, or serious weakness, are 
autoimmune myopathies caused by interference of the acetylcholine 
receptors (332).  
 Myopathies due to endocrine abnormalities are normally curable and 
occur in response to changes in hormones such as thyroxine (333). 
 Diseases of peripheral nerve are forms of inherited myopathies that 
occur due to the destruction of nerves or axons that stimulate 
movement (334). 
 Metabolic diseases of muscle are mostly inherited myopathies that 
arise from the lack or malfunction metabolic enzymes or mitochondrial 
genes (335).  
 Other non-related conditions affecting muscle tone. 
Diseases-states leading to muscle wasting are conditions such as 
 Cancer induced atrophy (cachexia) 
 Any debilitating condition leading to physical inactivity including surgery 
and acute illness 
 mechanical/medical injury to nerves or tendons (accidents, surgery and 
post-synaptic block in intensive care unit) 
 toxins (snake bite) 
 malnutrition or starvation  
 therapeutic treatments which may have muscle wasting as a secondary 
effect (dexamethasone or statins) 
 natural decline of muscle mass with age 
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The following section aims to show the particularities of some of the most 
studied forms of muscle wasting: genetic disorders, cachexia, sarcopenia and 
inactivity. 
Genetic disorders 
Inherited myopathies are a large group of deleterious leading to progressive 
muscle loss, weakness and shorter life-span (336). The most common 
myopathy, DMD (337), occurs as a result of aberrant expression (or lack) of 
dystrophin. This protein anchors the sarcomere to the cell membrane (338). 
DMD, first described in the late 19th Century by French neurologist Guillaume 
Duchenne, has an incidence of 1 out of 3,500 live male births and a 
prevalecense of 1 in 20,600 in the western world. DMD patients are born 
normal, but they start experiencing muscle mass loss during their infancy. 
DMD progression involves general muscle wasting, lack of postural control 
and need of supportive equipment or a wheelchair during childhood. Then, 
DMD patients experience cardiac, respiratory and digestive problems, which 
will cause death by 20 years of age without appropriate care. As long as there 
is no cure against DMD, patients will have to endure the progression of their 
disease only with nutritional interventions, corticoids and palliative care.  
Potential therapeutic developments against DMD have focused on rectifying 
the gene mutation as well as enhancing muscle function. Promising cures are 
the restoration of dystrophin via exogenous expression of the protein or parts 
of it (15, 123, 339), delivery of genetic ‘fixes’ to produce a normal endogenous 
gene (exon skipping) (340) or delivery of utrophin, an alternative gene that 
shares functions with dystrophin (16). Of interest is the evidence supporting 
the treatment of DMD patients via Fst-based therapies (19, 341, 342) or 
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overexpression of PGC-1 (229). This highlights the therapeutic potential of 
these interventions. 
Cachexia 
Cachexia is the loss of muscle mass occurring from increased circulation of 
muscle-wasting inducing factors. This is occurs in some types of cancer 
(Figure 11), uraemia, and stroptozotocin-induced diabetes (328). Cachexia is 
also results from chronic heart failure (343, 344), COPD (174, 345) or after 
the administration of corticosteroids or blood pressure lowering medications 
(284, 346). One important circulating protein involved during cancer cachexia 
is myostatin (134). Myostatin can exacerbate the UPP and lysosomal 
pathways while also reducing the levels of circulating anabolic hormones 
(343). Together this leads to a rapid decline muscle mass and body weight.   
 
 
Figure 11 from Aversa, Z. et al 2011 shows pronounced muscle wasting in a 59 year-
old man with metastasizing gastric cancer. The patient had lost approximately 35% of 
his normal body weight during his illness (186).  
 
CHAPTER I – INTRODUCTION 
61 
 
Cancer is also accompanied by a drop in Akt phosphorylation and PGC-1 
levels in skeletal muscle (347). There is a body of evidence suggesting that 
treating muscle wasting is beneficial against cancer (95). A hallmark of 
cachexia is that the loss of lean body mass cannot be prevented or reversed 
simply by increasing nutritional intake (95). Interestingly, myostatin inhibition 
has shown to protect against cachexia and increased survival (140, 348, 349). 
There is also evidence suggesting that exercise mediated up-regulation of 
PGC-1 can ameliorate cachexia (350). 
Sarcopenia 
The decline in muscle mass and decrease in muscle function as a 
consequence of advanced age is known as sarcopenia (351-353). It is 
controversial whether sarcopenia is a consequence or a disease. Sarcopenia 
is characterised by decreased myogenic (anabolic) markers at rest and upon 
load (354), increased production of oxidative species, decreased antioxidant 
levels (355) and reduced capacity to activate satellite cells (353). This loss in 
skeletal muscle plasticity (356) comes in hand with decreased ability to 
respond to exercise (357). Myostatin and decreased Akt phosphorylation are 
also present during sarcopenia (358). Interestingly, anti-myostatin 
interventions have shown to protect against sarcopenia in mice (105, 359).  
Also, transgenic overexpression of PGC-1 (243) or its up regulation after 
treatment with Losartan (155) have shown to protect against sarcopenia.  
Non-degenerative models of muscle wasting  
There are several non-degenerative models of muscle wasting. These 
include, for example, injury or trauma to nerves (denervation) (360) and/or 
tendons. Loss of innervation leading to paralysis may occur as a result of 
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damage or death of the motor unit, sectioning of the nerve (277) or disruption 
between acetylcholine and its receptor [such as a result of post-synaptic block 
or neuromuscular blockade while in intensive care unit (361)]. Loss of 
innervation is often used as a model to resemble the progression of 
neuromuscular diseases such as ALS (362-364). In contrast to denervation, 
tendon trauma leads to the mechanical unloading of a muscle while still 
retaining the intact nerve that supplies with both electrical activity and trophic 
factors (360).  
Denervation of skeletal muscle cells is characterized by atrophy (362, 364) 
and changes in morphology (365, 366). During denervation there is 
accelerated protein breakdown and rapid loss in mass, probably as a 
consequence of increased protein degradation (367) apoptosis (368) and 
autophagy (369). Early in denervation there is nuclear translocation of FoxO3 
and increased transcription of atrogenes. Later, FoxO3 is acetylated and 
inhibited (370). This needs to be taken into account when designing 
interventions against denervation.  
Denervation is also associated with apoptosis of myofibrillar proteins (275, 
371, 372) in the subsarcolemmal areas around myonuclei (373). Denervation 
is followed by an increase in acetylcholine receptor density (374, 375). 
decrease mitochondrial content (376), increase subsarcolemmal and inter 
myobrillar concentration of oxidative oxygen species (e.g. nitric 
oxide/peroxynitrite hydrogen peroxide) (368), an increase in preteoglycan 
expression (377) and reduction of nitric oxide synthase (NOS) (378). NOS has 
been implicated in the control of intracellular levels of calcium, myonuclei 
number, satellite cell incorporation (379) and susceptibility to apoptosis (380). 
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Denervation is often accompanied by DNA fragmentation (368) and occurs in 
parallel to deleterious changes in transcription factors. These includes the fall 
in both Transcription factor A (Tfam) and PGC-1, as well as an increase in 
the ratio of between the anti-apoptotic B cell lymphoma 2 associated x protein 
(Bax) and the pro-apoptotic B cell lymphoma 2 protein (Bcl-2). In addition, 
denervation has been shown to put a break in the cell cycle (in laryngeal 
muscle of rats) (381) and increase the levels of Myogenic regulator factor D 
(MyoD), cyclin-dependent kinase inhibitor p21 and retinoblastoma protein. Not 
all of these changes are associated with muscle atrophy. It is possible that 
some responses may correspond to a natural protective response against 
denervation (382) [such as flavoprotein apoptosis-inducing factor (AIF), a key 
anti-apoptotic molecule (383)]. During denervation-atrophy there is also a fall 
in phosphorylation of tumour protein 53 (p53) (384). Interestingly, 
overexpression of p53 improves aerobic exercise capacity and augments 
skeletal muscle mitochondrial DNA content by interacting with Tfam (385). 
Despite the vast understanding about denervation-atrophy, there is no 
therapeutic intervention against this form of muscle wasting. Denervation 
could act as a surrogate model to understand the effects of immobility, neuro-
degeneration and accidental nerve/tendon damage. And testing therapeutics 
interventions during denervation could be used to assess the role of nerve-
trophic factors during muscle growth. 
Potential interventions against muscle wasting 
As previously discussed, there is a large unmet medical need for an 
intervention to maintain or re-establish skeletal muscle mass and function. 
Current treatments to reduce the loss of muscle mass such as nutritional 
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supplementation (providing increased calorie intake and special amino acid 
compositions) and hormonal treatment (e.g. growth hormone, testosterone, 
IGF-1, and insulin)  have been largely ineffective [reviewed in (386)]. It would 
be cost efficient to develop a ‘one for all’ treatment than targeting each 
disease independently. Denervation-induced atrophy offers a model fit for the 
porpoise of testing these interventions.  
Denervation-atrophy is characterized by the loss in nerve activity and 
paralysis. Many interventions have shown promising results against 
denervation-atrophy. Some of the most successful results have been obtained 
with electrical stimulation or pharmacological/genetic interventions that 
mimicking endurance or resistance training. The following section summarizes 
some of these known approaches and explores the potential of novel 
interventions. 
Electrical stimulation 
Denervation increases protein degradation but does not interfere with the 
ability to synthesize proteins (365). For this reason, mechanical interventions 
that classically increase protein synthesis can effectively restore muscle mass 
and function in this model of atrophy. Such is the case of synergistic tenotomy 
which increases muscle mass by 40% within 6 days in healthy mice (387) and 
similarly (but to a lesser extent) increases mass of denervated rat muscle 
(Figure 14). This showed that denervated muscle can grow even during 
absence of neuronal influences (388). Stretching muscle fibres has also 
shown to increase the cross sectional area of denervated soleus muscle 
fibres (see Figure 4), a process involving activation of Akt signalling but not 
mTOR (389). The most successful therapeutic intervention against 
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denervation has been electrical stimulation. Electrical stimulation can maintain 
mass and force production of skeletal muscle after denervation in rats (390), 
dogs (391) and humans (392). Perhaps the future awaits with implantable 
stimulation devices to preserve muscle mass and force, a successful 
approach to maintain function in the EDL of young (393) and old rats (394). 
 
Figure 12 shows how muscle contraction protects skeletal muscle against 
denervation in rats after repetitive stretch in denervated soleus (A) (389) and 
electrically contracted denervated EDL (390) (Cd stands for contractions daily).  
 
Synthetic compounds and transgene manipulation 
Pharmacological compounds have been shown to protect against 
denervation-atrophy. For example, systemic administration of -adrenergic 
receptor agonist has an anabolic effect that reduces the muscle loss by 15% 
in denervated rats. This protection seems to be rapamycin insensitive (395), 
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an possibly Akt independent (396). The administration of proteasome 
inhibitors, which block the UPP, can also attenuate denervation atrophy by as 
much as 50% in rat muscle (291, 397). 
Transgenic manipulation of genes has also shown promising results against 
denervation (Figure 13). A 10 % protection against atrophy in the 
gastrocnemius muscle of denervated mice has been observed in mice lacking 
Bax (322). Bax is an apoptotic protein that induces DNA fragmentation, 
mitochondrial mediated apoptosis, activation of caspases, increases oxidative 
stress and inhibits the apoptosis repressor with caspase recruitment domain 
(ARC) in mice (398). Transgenic deletion of caspase-3, another example of a 
pro-apoptotic target involved in muscle wasting, spares muscle wasting by 
10% in denervated mice. Unfortunately, it is unlikely that sustained 
suppression of caspases will become a clinical application because this could 
interfere with the normal turnover of proteins required for a health (320). 
Another potential approach is to block the active form of I-kappa beta (I) 
kinase  (IkkB) and in turn de-activate NF- signalling and expression of E3 
ubiquitin ligases (399). Although genetic and pharmacological suppression of 
this pathway does not produce an inherent phenotype, inhibition of NF- in 
transgenic mice reduces atrophy in the gastrocnemius by around 13% after 2 
weeks of denervation as well as protecting against other models of wasting 
such as cancer cachexia. Similarly, effects have been found after the 
inhibition of NF- signalling components (299, 400) [for comprehensive 
review of this pathway refer to Mourkioti et al. (297)] highlighting this pathway 
as a potential therapeutic targe. This is further supported by the evidence 
showing that Tumour Necrosis Factor (TF) like weak inducer of apoptosis 
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(TWEAK), a key cytokine related to NF- activation, plays a role in 
denervation. Transgenic overexpression of TWEAK leads to a decrease in 
muscle size and it exacerbates denervation-atrophy (predominantly in fast 
fibres). This occurs via activation of NF- and its target MuRF1. Ablation of 
TWEAK (genetic or chemical blockade) increases muscle size and rescues 
the loss of mass and strength after denervation (401). 
The Akt pathway is another potential target against denervation-atrophy. 
Increasing IGF-1, an upstream regulator of Akt, reduces atrophy by 20% after 
two weeks of denervation (111). A similar effect is obtained by increasing the 
activity of Akt (104). Crossing of mice carrying active Akt and lacking Inhibitor 
of NF- (IKK2) have shown further improvement in the protection against 
wasting (299). However, the benefits IGF-1 treatment could decrease with 
age (402). 
PGC-1 overexpression can partially protected against muscle wasting (243). 
PGC-1 has been shown to protect against denervation via modulation of 
FoxO3, conferring up to a 30% protection in denervated muscles. Although 
the exact mechanisms remain elusive, PGC-1 seems to drive a genetic 
program with the capacity to confer protection against atrophy via down-
regulation of E3 ubiquitin ligases (189). 
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Figure 13. Genetic interventions that protect against denervation-atrophy. Adult 
overexpression of a constitutively active form of Akt (104) (A), transgenic (Tg) 
expression of a muscle IKK super repressor (MISR) (399) (B), transgenic deletion 
(KO) of caspase-3 in the gastrocnemius of mice (323) (C), transgenic deletion of the 
Bax gene (322) (D), transgenic muscle specific overexpression of PGC-1 (189) (E) 
and transgenic deletion of TWEAK protein in mice (401) (F).  
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The TGF- signalling pathway has also shown to participate in denervation 
atrophy. The absence of nerve supply evokes an increase in myostatin levels 
(active form) in both rats (403) and mice (404). Accumulation of myostatin in 
denervated muscles is reduced with exercise (405), suggesting that myostatin 
inhibition could potentially buffer the effects of denervation. Interestingly, as 
myostatin levels increase during denervation so does the phosphorylation of 
mTOR, suggesting that skeletal muscle has mechanism in place to defend 
from atrophy (406). However, it is not known whether post-natal inhibition of 
myostatin via, for example, treatment with Fst could protect against 
denervation atrophy.  
An innovative approach, increasing muscle mass and fatigue resistance 
Regular exercise has great health benefits, including healthy aging and 
improved physical performance. While reduced physical activity/exercise, 
muscle disuse or disease has the opposite effect. In general, exercise is 
believed to improved strength and/or endurance. Training to increase strength 
involves the use of resistance to muscular contraction and increases force, 
anaerobic endurance and skeletal muscle mass (388). While training to 
improve endurance improve stamina, exercise efficiency and resistance to 
fatigue with little or no change to muscle mass (193). Separately, endurance 
and resistance training have positive health effects (407). But in combination 
(concurrent training), endurance and resistance training may even better 
(408). Concurrent training has been shown to improve energy metabolism 
(409) [a response preserved in the elderly (410, 411)]  and be best suited to 
improve the health sedentary people (412) over the performance of highly 
trained athletes (413, 414).  
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Mimicking the effects of concurrent training is a very palatable idea from a 
therapeutic point of view (415). However, it is currently unknown whether it is 
possible to make a muscle fatigue resistant and strong at the same time 
(416). For this reason, it would of interest to test if post-natal manipulation of 
each PGC-1 and Fst or their combination could reproduce subset 
adaptations of endurance and resistant exercise.  
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Skeletal muscle metabolism 
Skeletal muscle makes up to half of the body weight in non-obese humans 
and is fundamental in metabolic homoeostasis (417, 418). The regulation of 
skeletal muscle mass and metabolism is both complex and depend one on 
each other. There are two main nutrients involved in energy production, 
glucose and lipids. Hence, their correct regulation it is fundamental for muscle 
function. 
Glucose metabolism 
Glucose is one of the main energy substrates. Uptake of glucose by skeletal 
muscle relies on the translocation of glucose transporters to the sarcolemma 
and the t-tubules (419) [reviewed in (420)]. In muscle, glucose Transporter 1 
(GluT-1) is responsible for maintenance of basal glucose uptake while 
Glucose Transporter 4 (GluT-4) acts upon the increase in levels of insulin 
concentration and/or muscle contraction (421, 422). Once inside the cell 
glucose trapped inside the cell by its phosphorylated by hexokinase or it is 
stored as glycogen. Glycogen and glucose generate energy via anaerobic and 
aerobic metabolism. Anaerobic metabolism occurs at the expense of 
generation of deleterious molecules such as lactate and hydrogen while 
complete oxidation glucose occurs through aerobic respiration (423).  
Insulin-dependent glucose uptake is a process that begins with the binding of 
insulin to the insulin-receptors located in the membrane of skeletal muscle 
cells. This renders a conformational change in the insulin receptor that 
activates the kinase domain in its intracellular portion. The intracellular 
domains initiates a phosphorylation cascades via activation of the Insulin 
Receptor Substrate 1 (IRS-1) which in turns activates PI3K rendering the 
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phosphorylation of it downstream target Akt1 at Thr308 and Ser473 (424). 
Activation of Akt triggers the translocation of GluT-4 (425) as well to signal 
downstream through activation of mTOR/p70S6K (426). This links glucose 
uptake with muscle growth (427). Akt exerts control of metabolism at multiple 
levels. In healthy individuals, the Akt pathway is constantly fluctuating 
between active and inactive. In contrast, insulin insensitive postpartum 
women present constant activation of this signalling cascade (428). Akt also 
controls FoxO, a key transcription factors involved in atrophy and in the 
negative regulation of the insulin related receptor. It still remains to be fully 
elucidated whether post-natal interventions that activate Akt to induce muscle 
growth can also increase insulin sensitivity. 
Increased glucose uptake can also occur independently of insulin via 
activation of GluT-4 in response to muscle contraction. This mechanism 
increases allows to compensate for increased energy demands (429). This 
process involves two mechanisms [reviewed in (430)]. The first, augmenting 
the intracellular concentration of calcium directly up-regulates GluT-4 
translocation (431). The second, a drop in the ATP to Adenosine 
monophosphate (AMP) ratios as a consequence of decreased in fuel 
availability activates AMPK which in turns increases glucose uptake (432).  
An increased in glucose uptake is also observed during skeletal muscle 
growth. It is possible that this effect is linked to higher net calcium uptake, 
more contractile units and increased energy storage capacity. And key 
signalling cascade that could be behind these changes is the TGF- pathway 
(6, 433, 434). There is evidence from obese and insulin-resistant human 
subjects to support an increase in the activity of the TGF- pathway during 
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these conditions (435, 436). This pathway inhibits muscle growth and this 
could in turn decreased glucose uptake during atrophy (245, 437). On the 
other hand, inhibition of the TGF- family ligand myostatin is associated with 
improved insulin sensitivity during high-fat diet induced obesity (6, 438-440). 
Similarly, mice lacking Smad3 (a TGF- signalling component) are  protected 
against insulin resistance (441). The rationale is that TGF- pathway inhibition 
increases Glut-4, Akt signalling and AMPK driven up-regulation of metabolic 
regulators such as PGC-1 (442). However, it is currently unknown whether 
post-natal delivery of the TGF- pathway inhibitor Fst can have a positive 
influence over glucose metabolism.  
Lipid metabolism 
Lipids are a broad group of molecules that play key roles in cellular structure 
and energy metabolism. The process of lipid metabolism includes the 
breakdown of adipose and intramuscular triglyceride, the transport of free fatty 
acids (FFAs) from adipose to muscle, the entry of FFAs into muscles from 
blood, activation of FFAs, entry of activated FFAs into mitochondria, Beta 
oxidation (-Oxidation) of FFAs and mitochondrial of oxidation (443). 
Oxidation fatty acids is the most efficient source for skeletal muscle ATP 
production (444). Triglycerides are mainly used at rest and during low 
intensity exercise by mitochondrial-rich muscles (443). Endurance training or 
endurance like interventions, such as PGC-1 overexpression or PPAR 
agonists, have the ability to improve triglyceride metabolism (195, 198, 233, 
272, 440, 445, 446). Muscle atrophy is associated with the opposite effect 
(379, 447, 448). Recently it has also been shown that mice over-expressing 
Akt isoform 1 (Akt1), post-natal myostatin blockade and transgenic deletion 
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myostatin, all results in increased muscularity and reduced fat content when 
challenged with high fat diets (440, 449). This is likely to occur in order to 
improved energy metabolism to support growth as well as an increased 
efficiency of the myofiber membrane to transport nutrients (450).  
There is rodent evidence to support that changes in the membrane lipidome 
of skeletal muscle regulates energy metabolism (451). In humans, changes in 
diet (452) and exercise can regulate the lipidome (453, 454). As described by 
Andersson, A et al. in 1998, low intensity exercise seem to reduce the 
phospholipid proportion of palmitic acid (16:0) and linoleic acid [18:2(n-6)] and 
the sum of n-6 fatty acids [18:2(n-6), 20:3(n-6), 20:4(n-6)], whereas oleic acid 
[18:1(n-9)] increases by training while the fatty acid profile in skeletal muscle 
triglycerides remains unchanged. However, these observations have not been 
proved true. It is possible that lipidomic adaptions precede, follow or mediate 
many changes in skeletal function. Perhaps muscle growth, such as it occurs 
with Fst treatment, has unknown effects on the lipidome. However, this will 
remain unknown until such experiment is performed. Testing potential 
therapeutics interventions to improve different aspects of muscle function 
could lead to better therapies. Growing pressure to come up with new 
therapies, stricter regulatory legislations and scientific advances require new, 
innovative, specific models for the development of therapies. Fortunately, new 
gene manipulation technologies are helping in the understanding of skeletal 
muscle function. A particular technology, rAAV viruses, has risen above the 
rest due to the potency, tissue-specificity and lack of immunogenicity. Clearly, 
these viruses hold great potential for the development of therapies in the new 
millennia (15, 16). 
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Gene therapy with rAAV 
Gene therapy allows the introduction of new genetic material to correct gene-
malfunctions, re-/introduce new/missing genes or depressed endogenous 
transcripts. During the last 15 years, Recombinant adeno-associated viral 
vectors have generated much optimism as the preferred gene therapy 
platform for human use. rAAVs have been safely tested in clinical trials 
involving over 300 patients (211, 212) (see table 1 for a list of trials). The 
reason why rAAVs are so attractive is because they are non-replicative, non-
integrative, non-pathogenic and generally safe (455). rAAV could allow to 
tissue specific delivery (456) of one or multiple genes at once. According to 
the United States of America Department of Health and Human Services 
Agency for Food and Drug Administration (FDA), risks associated with 
delivery of rAAVs are minimum (457). While the approval of therapies based 
on rAAVs by the FDA is still in progress, their uptake as gene delivery tools 
for research in vivo has grown rapidly.  
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Table 1 [adapted from High and Aubourg (18)] shows a current list of registered clinical trials using 
 
Disease 
Transgene Serotype Route of administration Clinical trial (number of patients) 
1-Antitrypsin deficiency 
(21) 1-Antitrypsin 
rAAV-2, 
rAAV-1 Intramuscular (IM) Phase I/II 
Age-related macular 
degeneration (recruiting) 
Placental Growth 
Factor Fusion protein  rAAV-2 Intravitreal injection Phase I 
Alzheimer’s disease (8) NGF rAAV-2 Intracranial Phase I/II 
Arthritis (127) 
Tumour Necrosis 
Factor Receptor Fusion 
Protein  
rAAV-2 Intraarticular Phase I 
Batten disease (~10) Tripeptidyl-peptidase I rAAV-2 intracranial Phase I 
Canavan’s disease (10) Aspartoacylase rAAV-2 Intracranial Phase I 
Cystic fibrosis (>130) 
Cystic Fibrosis 
Transmembrane 
conductance regulator 
rAAV-2 
maxillary sinus, 
bronchoscopy to right 
lower lobe, aerosol to 
whole lung 
Phase I/II 
Severe heart failure (9) Sarcoplasmic reticulum Ca2+ ATPase rAAV-1 
coronary artery 
infusion Phase I/II 
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Hemophilia B (8  +  8) Coagulation Factor IX rAAV-2 IM and hepatic Phase I/II 
HIV vaccine HIV virus protein gag rAAV-2 IM Phase I/II 
Liprotein Lipase deficiency 
(8) Lipoprotein Lipase rAAV-1 IM Phase I/II 
Lebel's Congenital 
amaurosis (blindness)(12  + 
 3  +  3) 
Retinal Pigment 
epithelium-specific 
65Kda protein 
rAAV-2 Subretinal Phase I/II 
DMD (3) Microdystrophin rAAV-1/2 hybrid IM Phase I 
Muscular dystrophy: Limb 
Girdle (~6) alpha-Sarcoglycan rAAV-1 Repeated IM Phase I 
Parkinson’s disease (22) 
AA decarboxylase, GA 
decarboxylase, 
Neutrophin 
rAAV-2 Intracranial Phase I/II 
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Pompe’s disease (recruiting 
subjects) 
Alpha-glucosidase 
(GAA) rAAV-1 intradiaphragmatic Phase I/II 
Becker Muscular Dystrophy 
and Sporadic Inclusion 
Body Myositis (15) 
Follistatin (circulating 
form) rAAV-1 IM Phase I 
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rAAVs classify as a class of Dependoviruse (family Parvoviridae, subfamily 
Parvovirinae). They have a single stranded DNA viral genome of about 4.7kb 
packaged in a 25nm protein capsid (458) (Figure 14). The rAAV genome is 
composed of open-reading frames encoding replication and capsid proteins flanked 
by inverted terminal repeats (ITRs) at either end of the viral genome. There are 
mainly 9 rAAV serotypes, each with variable tissue tropism (459). These serotypes 
share similar genome size and organization, however they differ in the amino acid 
capsid (459). 
 
Figure 14 shows (A) a viral particle, (B) the representations viral capsid and transgene and 
(C) the transgene constituents (promoter, transgene cDNA and polyA signal). 
  
Tissue specific uptake of rAAVs is controlled by capsid serotype and transgene 
expression by the promoter. In combination, capsid and promoter allow tissue 
specific, stable delivery of genes into muscle and other tissues in rodents (460), 
canines (340, 461), macaques (17, 462) and humans (463). Cellular uptake of  
rAAVs requires its binding to rAAV receptors on the surface of the target cell (464). 
Then, endocytosis of rAAVs into the nucleus occurs through vesicular trafficking, 
endosomal escape and nuclear transport. Once in the nucleus, rAAVs particles shed 
their capsid to delivery its transgene (Figure 15).  
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Serotype 6 rAAV (rAAV6) are a favourite to treat skeletal muscle. Single delivery of 
rAAV6 has shown to cause body-wide transduction of the entire skeletal musculature 
(465). Body-wide delivery of rAAV6 has been successful at treating mice (339) and 
canines (466). Overexpression of insulin and glucokinase via delivery of rAAV6 has 
shown improve glycaemia in diabetic mice (467). These characteristics position 
rAAVs at the forefront of therapeutic tools when focusing on enhancing muscle 
function.  
 
 
Figure 15 (Ding et al. 2005) represents the steps of rAAV transduction including: (1) viral 
binding to a receptor/coreceptor, (2) endocytosis of the virus, (3) intracellular trafficking of 
the virus through the endosomal compartment, (4) endosomal escape of the virus, (5) 
intracellular trafficking of the virus to the nucleus and nuclear import, (6) virion uncoating, 
and (7) viral genome conversion from a single-stranded to a double-stranded genome 
capable of expressing an encoded gene (464). 
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Aims and hypothesis 
The outstanding ability of skeletal muscle to respond to environmental stress (468) 
plays both in favour and against its function. There is hope that manipulating 
signalling cascades to resemble exercise may outweigh disease. Two possible 
interventions to do this and improve skeletal muscle function are down-regulation of 
TGF- signalling by increasing Follistatin levels and up-regulation of PGC-1. Thus, 
the general aims and hypothesis of this research will be as follow: 
Aims 
1. To test the hypothesis that Follistatin overexpression can prevent (or treat) non-
degenerative muscle wasting (nerve and/or tendon injury) by increasing muscle 
growth. 
2. To test the hypothesis that Follistatin-induced muscle growth will increase the 
demands and utilization of glucose and lipids. 
3. To test the hypothesis that muscle growth and fatigue resistance driven by 
overexpression of Follistatin and PGC-1, are not mutually exclusive in the control of 
muscle mass and function. 
Hypothesis  
1. It is hypothesised that Follistatin will affect signalling pathways that increase 
protein synthesis and decrease protein degradation. In turn, this will have a 
protective effect against models of wasting such as denervation. In addition, it is 
expected that denervation will exacerbate this pathways and that Fst will buffer this. 
2. It is hypothesised that Follistatin overexpression will produce muscle growth. This 
will in turn increment the demands for glucose and fatty acids. 
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3. It is hypothesised that co-expression of PGC-1 and Follistatin will have additive 
effects in increasing muscle mass and enhancing force production capacity. 
Implications of this work 
This work will show whether Follistatin can be used to treat non non-degenerative 
muscle wasting. Also this thesis will demonstrate the effects of Fst-induced growth 
on glucose and lipid metabolism. Finally, this research will be the first to show the 
effect of post-natal PGC-1 delivery and the effect of its combined delivery with Fst 
on muscle mass and function. This work will create a novel body of knowledge. 
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